Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So our exit run rate would be much better than what we see it for the full year, for this year |
| We are truly differentiated in our ability to bring trials to patient populations that are challenged with access to these potentially life-saving opportunities and it is a key opportunity to add margin and manage risk for our payer partners |
| Jeremy adds key strengths to our executive team on operational excellence, drug procurement strategy and radiation oncology optimization in addition to other skills |
| Starting with the top line, I'm very pleased to report that in the quarter, we achieved 26% revenue growth compared to Q3 of 2022, supported by strong demand for our services |
| And we are seeing incredible growth opportunities in our pipeline as outlined with our new relationship we are starting in Florida and several additional opportunities, which we expect to announce in the upcoming quarters |
| Our performance in the quarter demonstrates our ability to execute our strategy as we significantly grew the top line while improving profitability |
| Gross profit has improved sequentially since we announced the headwind around IV drug margins in Q1 2023 |
| Again, this past quarter we delivered strong growth year-over-year, expanded our gross margin and reduced SG&A, all of which is helping drive us towards our elimination of cash burn and path to profitability towards the end of next year |
| Through a concentrated effort to improve collection timeliness, we have seen improvement in our cash position and expect the improvement to continue in Q4 2023 |
| In summary, I'm very pleased with our performance in the third quarter |
| Third, a significant portion of our providers have successfully integrated Ambience, an AI powered platform designed for clinical documentation, workflows and enhancing the patient experience |
| We are excited to prove our model which means dramatically lower costs for our payer partners while maintaining high standards of care |
| Their collective performance has resulted in another impressive quarter of financial growth |
| This came after our restructure, which we completed in Q2, and we expect to achieve continued benefit in this key ratio as we scale through 2024 |
| This provides enhanced continuity of care for patients requiring radiation to the differentiator to cure play medical oncology practices and drives margin on our fee-for-service business |
| As Dan shared we are pleased with our third quarter results |
| This displaces the more common Network Model Solution, which has been prevalent in Florida for many years, and we anticipate it to act as a catalyst for our continued growth, as we demonstrate TOI's ability to deliver superior outcomes for both payers and patients |
| Lastly, with the recent appointment of Jessica Yankus as our new national pharmacy leader, we are now fully prepared to commence our 2024 operations with a strong focus on expanding our oral specialty drug business and enhancing margins through improved drug procurement strategies |
| We believe follow on growth opportunities in new markets using this new direct to health plan model will be a key driver of capitated growth for us in upcoming years |
| I'm excited by the progress made this quarter and want to begin again by thanking our clinical staff and teammates for their remarkable contributions to furthering community-based oncology care for our patients every day and driving efficiency and innovation in our clinical model |
| As we continue to implement this tool, we aim to increase efficiency, optimize charge capture, and improve overall patient satisfaction, thus creating more capacity to accommodate our growing number of encounters |
| We continue to drive margin improvement in our legacy markets through three key efforts |
| Jeremy joined us with over 15 years of oncology industry experience and has a track record of driving growth and profitability for multi-state physician groups |
| We strongly believe we can continue to advance this lead by being an employer of choice for oncologists, driving innovation in community-based cancer care for the patients and payers that we serve and look forward to continued focus on our top four priorities as we move forward |
| And three, with this relationship as well as several that are in the pipeline in 2024 because it's a national payer, if we do a fantastic job, which I'm confident we will there should be follow-on expansion opportunities to build the relationship |
| It's a really great one |
| We did put significant focus in the timeliness and accuracy of our collection, which we are also seeing benefit of |
| We have several near-term pipeline opportunities, which will expand our already dominant footprint as a value-based oncology provider in these markets |
| Adjusted EBITDA improved $1.4 million compared to Q3 2022 |
| Importantly, our organic growth rate was 20% and our same-store sales growth was 17% |
| Statement |
|---|
| Adjusted EBITDA for Q3 2023 was negative $5.4 million |
| As mentioned in our Q2 call, we are seeing the results of our efforts to reduce overheads, which produced SG&A, including depreciation and amortization of $30 million in Q3 2023, a decrease of 9.7% compared to Q3 2022 |
| Taking that to next year, you are right, we should see most of the burn would be from negative adjusted EBITDA, some CapEx and potentially some acquisitions |
| Loss from operations for Q3 2023 was $14 million, a decrease of $6.2 million compared to Q3 2022 |
| So I think that has some overhang that is not flowing through the bottom line for the full year yet |
| As a percentage of revenue, SG&A was 36.5% in the quarter, down 1,000 basis points from Q2 2023 |
| Q3 of 2023 was the lowest SG&A as a percent of revenue we have seen since going public |
Please consider a small donation if you think this website provides you with relevant information